MOTEGRITY Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Motegrity patents expire, and what generic alternatives are available?
Motegrity is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this compound. Additional details are available on the prucalopride succinate profile page.
Summary for MOTEGRITY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Patent Applications: | 1,245 |
| Drug Prices: | Drug price information for MOTEGRITY |
| What excipients (inactive ingredients) are in MOTEGRITY? | MOTEGRITY excipients list |
| DailyMed Link: | MOTEGRITY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MOTEGRITY
Generic Entry Date for MOTEGRITY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for MOTEGRITY
| Drug Class | Serotonin-4 Receptor Agonist |
| Mechanism of Action | Serotonin 4 Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for MOTEGRITY
US Patents and Regulatory Information for MOTEGRITY
MOTEGRITY is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOTEGRITY is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting MOTEGRITY
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | MOTEGRITY | prucalopride succinate | TABLET;ORAL | 210166-001 | Dec 14, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | MOTEGRITY | prucalopride succinate | TABLET;ORAL | 210166-002 | Dec 14, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
